Japan dabigatran programme to focus on stroke prevention
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has decided to focus the Japanese development programme for its novel anticoagulant Pradaxa (dabigatran etexilate) on stroke prevention in atrial fibrillation (SPAF) patients.